Celcuity Inc.
About Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$177.0M
- Total assets
- $466.6M
- Market cap
- $4.3B
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $172.2M
- Operating income
- -$172.2M
- Net income
- -$177.0M
- EPS (basic)
- $-3.79
- EPS (diluted)
- $-3.79
Balance sheet
- Total assets
- $466.6M
- Current assets
- $465.7M
- Total liabilities
- $366.0M
- Current liabilities
- $44.2M
- Shareholders’ equity
- $100.6M
Cash flow
- Operating cash flow
- -$153.3M
- Investing cash flow
- -$64.1M
- Financing cash flow
- $360.6M
- Net cash flow
- $143.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $4.3B
- EPS (diluted)
- $-3.79
- Shares outstanding
- 49.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 20, 2017
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $177.0M.
- Trading 40% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Celcuity Inc..
Write a review
News about Celcuity Inc.
News & sentiment via Polygon.io
